Printed from https://ideas.repec.org/s/spr/aphecp5.html
Content
June 2014, Volume 12, Issue 3
- 335-346 Assessing Medication Adherence and Healthcare Utilization and Cost Patterns Among Hospital-Discharged Patients with Schizoaffective Disorder
by Sudeep Karve & Michael Markowitz & Dong-Jing Fu & Jean-Pierre Lindenmayer & Chi-Chuan Wang & Sean Candrilli & Larry Alphs
April 2014, Volume 12, Issue 2
- 95-102 Managing Healthcare Budgets in Times of Austerity: The Role of Program Budgeting and Marginal Analysis
by Craig Mitton & Francois Dionne & Cam Donaldson - 103-115 Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia
by Ursula Rochau & Ruth Schwarzer & Beate Jahn & Gaby Sroczynski & Martina Kluibenschaedl & Dominik Wolf & Jerald Radich & Diana Brixner & Guenther Gastl & Uwe Siebert - 117-124 Variation in the Spillover Effects of Illness on Parents, Spouses, and Children of the Chronically Ill
by Tara Lavelle & Eve Wittenberg & Kara Lamarand & Lisa Prosser - 125-137 A Cross-Sectional Study to Evaluate the Awareness and Attitudes of Physicians Towards Reducing the Cost of Prescription Drugs, Mumbai
by Gauri Billa & Karan Thakkar & Sarita Jaiswar & Dinesh Dhodi - 139-150 The Impact of Overweight and Obesity on Pediatric Medical Expenditures
by Davene Wright & Lisa Prosser - 151-163 Cost-Utility Analysis Comparing Heavy-Weight and Light-Weight Mesh in Laparoscopic Surgery for Unilateral Inguinal Hernias
by Dmitrij Achelrod & Tom Stargardt - 165-177 Firm- and Drug-Specific Patterns of Generic Drug Payments by US Medicaid Programs: 1991–2008
by Christina Kelton & Lenisa Chang & Jeff Guo & Yan Yu & Edmund Berry & Boyang Bian & Pamela Heaton - 179-190 Impact of Early Versus Late Systemic Lupus Erythematosus Diagnosis on Clinical and Economic Outcomes
by Alan Oglesby & Caroline Korves & François Laliberté & Gregory Dennis & Sapna Rao & Ellison Suthoff & Robert Wei & Mei Duh - 191-201 That’s What Friends Are For: Adolescent Peer Social Status, Health-Related Quality of Life and Healthcare Costs
by Marlon Mundt & Larissa Zakletskaia - 203-217 Economic Evaluation of Using a Genetic Test to Direct Breast Cancer Chemoprevention in White Women with a Previous Breast Biopsy
by Linda Green & Tuan Dinh & David Hinds & Bryan Walser & Richard Allman - 219-230 Direct Medical Costs for Complications Among Children and Adults with Diabetes in the US Commercial Payer Setting
by Jason Yeaw & Shawn Halinan & Dionne Hines & Amy DeLozier & Magaly Perez & Mark Boye & Kristina Boye & Christopher Blanchette
February 2014, Volume 12, Issue 1
- 1-5 Remember the MaineRx
by Robert Kemp - 7-18 Propensity-Score Matching in Economic Analyses: Comparison with Regression Models, Instrumental Variables, Residual Inclusion, Differences-in-Differences, and Decomposition Methods
by William Crown - 19-32 Insulin Glargine in a Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review
by Ana Caires de Souza & Francisco de Acurcio & Augusto Guerra Júnior & Renata Rezende Macedo do Nascimento & Brian Godman & Leonardo Diniz - 33-40 A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries
by Katelijne Vooren & Silvy Duranti & Alessandro Curto & Livio Garattini - 41-49 The Cost Effectiveness of Implantable Cardioverter Defibrillators: A Systematic Review of Economic Evaluations
by Fotini Gialama & Panagiotis Prezerakos & Nikos Maniadakis - 51-58 Cost-Effectiveness Analysis of Clinically Indicated Versus Routine Replacement of Peripheral Intravenous Catheters
by Haitham Tuffaha & Claire Rickard & Joan Webster & Nicole Marsh & Louisa Gordon & Marianne Wallis & Paul Scuffham - 59-71 Economic Burden and Disparities in Healthcare Resource Use Among Adult Patients with Cardiac Arrhythmia
by Derek Tang & Adrienne Gilligan & Klaus Romero - 73-84 How Important Is Health Status in Defining Quality of Life for Older People? An Exploratory Study of the Views of Older South Australians
by Catherine Milte & Ruth Walker & Mary Luszcz & Emily Lancsar & Billingsley Kaambwa & Julie Ratcliffe - 85-93 Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States
by Hongbo Yang & Paresh Chaudhari & Zheng-Yi Zhou & Eric Wu & Chad Patel & David Horn
December 2013, Volume 11, Issue 6
- 561-576 An Overview of the Health Economic Implications of Elective Caesarean Section
by Stavros Petrou & Kamran Khan - 577-592 The Economic Burden of Complications Occurring in Major Surgical Procedures: a Systematic Review
by Ajay Patel & Annika Bergman & Brigitte Moore & Ulf Haglund - 593-618 Cost-Effectiveness Analyses of Osteoarthritis Oral Therapies: a Systematic Review
by Ronald Wielage & Julie Myers & Robert Klein & Michael Happich - 619-637 Are the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review
by Alison Pearce & Marion Haas & Rosalie Viney - 639-652 Preferences on Policy Options for Ensuring the Financial Sustainability of Health Care Services in the Future: Results of a Stakeholder Survey
by David Tordrup & Aris Angelis & Panos Kanavos - 653-660 Incremental Cost Effectiveness of Pharmacist-Managed Erythropoiesis-Stimulating Agent Clinics for Non-Dialysis-Dependent Chronic Kidney Disease Patients
by Sherrie Aspinall & Kenneth Smith & Chester Good & Xinhua Zhao & Roslyn Stone & Ivy Tonnu-Mihara & Francesca Cunningham - 661-670 A Model-Based Economic Evaluation of Improved Primary Care Management of Patients with Type 2 Diabetes in Australia
by Hossein Haji Ali Afzali & Jodi Gray & Justin Beilby & Christine Holton & Jonathan Karnon - 671-675 Direct Medical Cost and Glycemic Control in Type 2 Diabetic Saudi Patients
by Nora Almutairi & Khalid Alkharfy - 677-685 Impact of Delisting ARBs, Apart from Losartan, on ARB Utilisation Patterns in Denmark: Implications for Other Countries
by Ulrik Hesse & Brian Godman & Max Petzold & Andrew Martin & Rickard Malmström - 687-687 Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
by Dawn Lee & Patrick Thornton & Alexander Hirst & Lucie Kutikova & Robert Deuson & Nic Brereton - 689-689 Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
by Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres
October 2013, Volume 11, Issue 5
- 437-443 Generic Medicines: Solutions for a Sustainable Drug Market?
by Pieter Dylst & Arnold Vulto & Brian Godman & Steven Simoens - 445-456 Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing
by Ebenezer Tetteh & Stephen Morris - 457-469 Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
by Dawn Lee & Patrick Thornton & Alexander Hirst & Lucie Kutikova & Robert Deuson & Nic Brereton - 471-484 Does the Type of Provider and the Place of Residence Matter in the Utilization of Prenatal Ultrasonography? Evidence from Canada
by Harminder Guliani & Ardeshir Sepehri & John Serieux - 485-497 Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US
by Anju Parthan & Morgan Kruse & Nicole Yurgin & Joice Huang & Hema Viswanathan & Douglas Taylor - 499-507 Preferences for Colorectal Cancer Screening Techniques and Intention to Attend: a Multi-Criteria Decision Analysis
by J. Hummel & Lotte Steuten & C. Groothuis-Oudshoorn & Nick Mulder & Maarten IJzerman - 509-521 Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
by Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres - 523-529 Private Expenditures on Brand Name Prescription Drugs after Generic Entry
by Dahlia Balaban & Irfan Dhalla & Michael Law & Chaim Bell - 531-542 Economic Evaluation of Cardio inCode ® , a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment
by A. Ramírez de Arellano & A. Coca & M. de la Figuera & C. Rubio-Terrés & D. Rubio-Rodríguez & A. Gracia & A. Boldeanu & J. Puig-Gilberte & E. Salas - 543-552 Evolutions in Both Co-Payment and Generic Market Share for Common Medication in the Belgian Reference Pricing System
by Jessica Fraeyman & Moira Verbelen & Niel Hens & Guido Hal & Hans Loof & Philippe Beutels - 553-554 Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
by Hiltrud Liedgens & Rainer Henske - 555-557 Authors’ Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
by Ronald Wielage & Megha Bansal & J. Andrews & Robert Klein & Michael Happich
August 2013, Volume 11, Issue 4
- 311-318 New Anti-Rebate Legislation in South Korea
by Su-Yeon Yu & Bong-Min Yang & Jin-Hyun Kim - 319-329 Quantifying Benefit–Risk Preferences for Medical Interventions: An Overview of a Growing Empirical Literature
by A. Brett Hauber & Angelyn Fairchild & F. Reed Johnson - 331-341 Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis
by Annie Hawton & James Shearer & Elizabeth Goodwin & Colin Green - 343-357 A Practical Approach for Calculating Reliable Cost Estimates from Observational Data: Application to Cost Analyses in Maternal and Child Health
by Jason Salemi & Meg Comins & Kristen Chandler & Mulubrhan Mogos & Hamisu Salihu - 359-368 The Trade-off Between Costs and Quality of Care in the Treatment of Psychosomatic Patients with Somatoform Pain Disorder
by Laura Haas & Tom Stargardt & Jonas Schreyoegg & Rico Schlösser & Burghard Klapp & Gerhard Danzer - 369-381 The Role of Financial Wellbeing, Sociopolitical Attitude, Self-Interest, and Lifestyle in One’s Attitude Toward Social Health Insurance
by Oliver Schnusenberg & Chung-Ping Loh & Katrin Nihalani - 383-393 Changes in the Utilization of Venlafaxine after the Introduction of Generics in Sweden
by Brian Godman & Marie Persson & Jamilette Miranda & Peter Skiöld & Björn Wettermark & Corrado Barbui & Lars Gustafsson - 395-406 Compliance with Pharmacotherapy and Direct Healthcare Costs in Patients with Parkinson’s Disease: A Retrospective Claims Database Analysis
by Florent Richy & Guilhem Pietri & Kimberly Moran & Emmanuelle Senior & Lydia Makaroff - 407-413 Pre-Diagnosis Excess Acute Care Costs in Alzheimer’s Patients among a US Medicaid Population
by David Geldmacher & Noam Kirson & Howard Birnbaum & Sara Eapen & Evan Kantor & Alice Cummings & Vijay Joish - 415-425 A Comparison of the EQ-5D-3L and ICECAP-O in an Older Post-Acute Patient Population Relative to the General Population
by Leah Couzner & Maria Crotty & Richard Norman & Julie Ratcliffe - 427-435 Explaining the Health Costs Associated with Managing Intracranial Aneurysms in Italy
by Stefano Calciolari & Aleksandra Torbica & Rosanna Tarricone
June 2013, Volume 11, Issue 3
- 155-161 Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation
by Joanna Thorn & Joanna Coast & David Cohen & William Hollingworth & Martin Knapp & Sian Noble & Colin Ridyard & Sarah Wordsworth & Dyfrig Hughes - 163-180 Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making?
by Axel Mühlbacher & Christin Juhnke - 181-192 Cost Effectiveness of Fecal DNA Screening for Colorectal Cancer: A Systematic Review and Quality Appraisal of the Literature
by Mairead Skally & Paul Hanly & Linda Sharp - 193-203 Time Costs Associated with Informal Care for Colorectal Cancer: An Investigation of the Impact of Alternative Valuation Methods
by Paul Hanly & Alan Céilleachair & Mairead Skally & Eamonn O’Leary & Anthony Staines & Kanika Kapur & Patricia Fitzpatrick & Linda Sharp - 205-218 Multilevel Analysis of the Influence of Patients’ and General Practitioners’ Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France
by Sylvain Pichetti & Catherine Sermet & Brian Godman & Stephen Campbell & Lars Gustafsson - 219-236 Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective
by Ronald Wielage & Megha Bansal & J. Andrews & Robert Klein & Michael Happich - 237-249 Implications of a Data-Driven Approach to Treatment with Growth Hormone in Children with Growth Hormone Deficiency and Turner Syndrome
by Stefan Kaspers & Michael Ranke & Donald Han & Jane Loftus & Hartmut Wollmann & Anders Lindberg & Mathieu Roelants & Joris Kleintjens - 251-258 Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 Years
by Reiko Sato & Gabriel Gomez Rey & Stephanie Nelson & Brett Pinsky - 259-274 A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use
by David Price & Yumi Asukai & Jaithri Ananthapavan & Bill Malcolm & Amr Radwan & Ian Keyzor - 275-286 Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs
by Juliana Meyers & Yanni Yu & James Kaye & Keith Davis - 287-298 A Pilot Discrete Choice Experiment to Explore Preferences for EQ-5D-5L Health States
by Richard Norman & Paula Cronin & Rosalie Viney - 299-304 Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective
by Vijay Joish & Monica Spilsbury-Cantalupo & Elisabeth Operschall & Ba Luong & Susan Boklage - 305-305 Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison
by Carlos Alatorre & Virginia Haynes & Douglas Faries & Himanshu Upadhyaya & Douglas Kelsey - 307-307 Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”
by M. Erder & Jipan Xie & James Signorovitch & Kristina Chen & Paul Hodgkins & Mei Lu & Eric Wu & Vanja Sikirica - 309-309 Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder
by M. Erder & Jipan Xie & James Signorovitch & Kristina Chen & Paul Hodgkins & Mei Lu & Eric Wu & Vanja Sikirica
April 2013, Volume 11, Issue 2
- 85-93 Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases
by Hossein Haji Ali Afzali & Jodi Gray & Jonathan Karnon - 95-106 The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia
by Evanthia Achilla & Paul McCrone - 107-117 Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography Versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients
by Manuel Gomes & Robert Aldridge & Peter Wylie & James Bell & Owen Epstein - 119-128 Annual All-Cause Healthcare Costs Among Influenza Patients With and Without Influenza-Related Complications
by Sudeep Karve & Derek Misurski & Guillermo Herrera-Taracena & Keith Davis - 129-138 Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma
by Lionel Perrier & Anne Lefranc & David Pérol & Philippe Quittet & Aline Schmidt-Tanguy & Carole Siani & Christian Peretti & Bertrand Favier & Pierre Biron & Philippe Moreau & Jacques Bay & Séverine Lissandre & Fabrice Jardin & Daniel Espinouse & Catherine Sebban - 139-150 Measuring the Loss of Consumer Choice in Mandatory Health Programmes Using Discrete Choice Experiments
by Bonny Parkinson & Stephen Goodall & Richard Norman - 151-154 Is it Financially Efficient to Lose the Ring-Fenced Elective Orthopaedic Ward?
by J. Soler & Sanjiv Manjure & Yegappan Kalairajah
February 2013, Volume 11, Issue 1
- 1-3 Cost-Effectiveness Assessment of Orphan Drugs
by Steven Simoens & Eline Picavet & Marc Dooms & David Cassiman & Thomas Morel - 5-13 Pipeline™ Embolization Device for the Treatment of Complex Intracranial Aneurysms
by Kathleen Withers & Grace Carolan-Rees & Megan Dale - 15-26 The Economic Evaluation of Medical Devices
by Andreas Kirisits & W. Redekop - 27-43 A Systematic Review of Economic Evaluations in Second and Later Lines of Therapy for the Treatment of Non-Small Cell Lung Cancer
by Anne Jäkel & Melanie Plested & Kuntal Dharamshi & Rakhee Modha & Sarah Bridge & Adam Johns - 45-51 Lessons from Game Theory about Healthcare System Price Inflation
by Mark Agee & Zane Gates - 53-63 Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model
by Phil McEwan & Ray Kim & Yong Yuan - 65-78 Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal
by Elamin Elbasha & Jagpreet Chhatwal & Shannon Ferrante & Antoine El Khoury & Pedro Laires - 79-82 A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
by Brian Godman & Lars Gustafsson - 83-84 Authors’ Reply to Godman and Gustafsson: “A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing”
by Ulf Persson & Johanna Svensson & Billie Pettersson
November 2012, Volume 10, Issue 6
- 361-363 Insensitivity to Scope in Contingent Valuation Studies
by Jennifer Whitty - 365-379 Inclusion of Compliance and Persistence in Economic Models
by Ananth Kadambi & Robert Leipold & Anuraag Kansal & Sonja Sorensen & Denis Getsios - 381-395 Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder
by M. Erder & Jipan Xie & James Signorovitch & Kristina Chen & Paul Hodgkins & Mei Lu & Eric Wu & Vanja Sikirica - 397-405 Insensitivity to Scope in Contingent Valuation Studies
by Rikke Søgaard & Jes Lindholt & Dorte Gyrd-Hansen - 407-415 What Explains Willingness to Pay for Smoking-Cessation Treatments —Addiction Level, Quit-Rate Effectiveness or the Opening Bid?
by Jan Olsen & Ole Røgeberg & Knut Stavem - 417-430 Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain
by Tatiana Dilla & Amparo Valladares & Claudia Nicolay & Javier Salvador & Jesús Reviriego & María Costi - 431-440 Economic Implications of Rasburicase Treatment in Adult Patients with Tumour Lysis Syndrome
by Michael Eaddy & Brian Seal & Krishna Tangirala & Elizabeth Hackney Davies & Ken O’Day - 441-451 Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?
by Jaume Puig-Junoy
September 2012, Volume 10, Issue 5
- 285-287 Alcohol Reform in Viet Nam
by Nguyen Tam & Christopher Doran & Peter Hill & Michael Dunne - 289-293 Is More Expensive Medical Technology Better?
by Jeffrey Voigt & Michael Mosier - 295-297 NICE Medical Technologies Guidance
by Bruce Campbell & Mark Campbell - 299-308 PleurX Peritoneal Catheter Drainage System for Vacuum-Assisted Drainage of Treatment-Resistant, Recurrent Malignant Ascites
by Judith White & Grace Carolan-Rees - 309-317 Lifetime Productivity Losses Associated with Obesity Status in Early Adulthood
by Kristian Neovius & Clas Rehnberg & Finn Rasmussen & Martin Neovius - 319-329 Estimating Incremental Costs with Skew
by Linnea Polgreen & John Brooks - 331-342 Clopidogrel versus Aspirin in Patients with Atherothrombosis
by Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis - 343-353 Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis
by Ronald Vender & Charles Lynde & Vincent Ho & Dina Chau & Melanie Poulin-Costello - 355-358 Five-Year Evolution of Drug Prescribing in a University Adult Intensive Care Unit
by Christine Carron & Pierre Voirol & Philippe Eggimann & André Pannatier & René Chioléro & Jean-Blaise Wasserfallen
July 2012, Volume 10, Issue 4
- 217-225 A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
by Ulf Persson & Johanna Svensson & Billie Pettersson - 227-234 Economic Consequences of the Demography of MRSA Patients and the Impact of Broad-Spectrum Antimicrobials
by Klaus Kaier & S. Moog - 235-248 Cost Effectiveness of Drug-Eluting Stents in Acute Myocardial Infarction Patients in Germany
by Michael Bäumler & Tom Stargardt & Jonas Schreyögg & Reinhard Busse - 249-259 Resource Utilization and Outcomes in Patients with Atrial Fibrillation
by Rachael Boggon & Gregory Lip & Arlene Gallagher & Tjeerd Staa - 261-271 Economic Evaluation of Clopidogrel in Acute Coronary Syndrome Patients without ST-Segment Elevation in Greece
by Georgia Kourlaba & Vassilis Fragoulakis & Nikos Maniadakis - 273-284 Cost-Effectiveness Analysis of Treatments for Vertebral Compression Fractures
by Avram Edidin & Kevin Ong & Edmund Lau & Jordana Schmier & Jason Kemner & Steven Kurtz
May 2012, Volume 10, Issue 3
- 145-162 Economic evaluations of adult weight management interventions
by Ulla Griffiths & Benedict Anigbogu & Kiran Nanchahal - 145-162 Economic evaluations of adult weight management interventions
by Ulla K. Griffiths & Benedict Anigbogu & Kiran Nanchahal - 163-173 Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy
by Hema Viswanathan & Jeffrey Curtis & Jingbo Yu & Jeffrey White & Bradley Stolshek & Claire Merinar & Akhila Balasubramanian & Joel Kallich & John Adams & Sally Wade - 163-173 Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy
by Hema N. Viswanathan & Jeffrey R. Curtis & Jingbo Yu & Jeffrey White & Bradley S. Stolshek & Claire Merinar & Akhila Balasubramanian & Joel D. Kallich & John L. Adams & Sally W. Wade - 175-188 Cost effectiveness of prostacyclins in pulmonary arterial hypertension
by Antonio Roman & Joan Barberà & Pilar Escribano & Maria Sala & Laia Febrer & Itziar Oyagüez & Eliazar Sabater & Miguel Casado - 175-188 Cost effectiveness of prostacyclins in pulmonary arterial hypertension
by Antonio Roman & Joan A. Barberà & Pilar Escribano & Maria L. Sala & Laia Febrer & Itziar Oyagüez & Eliazar Sabater & Miguel Á. Casado - 189-200 National health insurance reform in South Africa
by Okore Okorafor - 189-200 National health insurance reform in South Africa
by Okore Apia Okorafor - 201-215 Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the ‘Act when Mild’ study
by John Slof
March 2012, Volume 10, Issue 2
- 77-85 Using the economics of certification to improve the safety and quality of male circumcision in developing countries
by Michael Richards - 87-97 Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel
by Oren Shavit & Raanan Raz & Michal Stein & Gabriel Chodick & Eduardo Schejter & Yehuda Ben-David & Raanan Cohen & Daphna Arbel & Varda Shalev - 99-111 Understanding consumer preferences in the context of managed competition
by Antonio Trujillo & Fernando Ruiz & John Bridges & Jeannette Amaya & Christine Buttorff & Angélica Quiroga - 113-126 Insights from triangulation of two purchase choice elicitation methods to predict social decision making in healthcare
by Jennifer Whitty & Sharyn Rundle-Thiele & Paul Scuffham - 127-138 A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries
by Sergio Iannazzo & Michela Carsi & Silvia Chiroli - 139-141 Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain
by Juan Pasquau & Joana Gostkorzewicz & Francisco Ledesma & Anne Anceau & Andrew Hill & Christiane Moecklinghoff - 143-144 The need for measurement of efficiency in Greek primary healthcare
by Nikolaos Oikonomou & Yannis Tountas & John Kyriopoulos
January 2012, Volume 10, Issue 1
- 1-13 Triangulating health expenditure estimates from different data sources in developing countries
by Christian Lorenz - 15-29 Intra-operative vs pre-operative endoscopic sphincterotomy in patients with gallbladder and common bile duct stones
by Kurinchi Gurusamy & Edward Wilson & Andrew Burroughs & Brian Davidson - 33-35 The role of health economics in alcohol policy
by Christopher Doran & Joshua Byrnes - 37-49 The efficiency of a volumetric alcohol tax in Australia
by Joshua Byrnes & Dennis Petrie & Christopher Doran & Anthony Shakeshaft - 51-63 Tackling alcohol misuse
by Anne Ludbrook & Dennis Petrie & Lynda McKenzie & Shelley Farrar - 65-76 Alcohol policy and taxation in South Africa
by John Ataguba
November 2011, Volume 9, Issue 6
- 351-365 Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin
by Sandra Tunis - 367-376 Early retirement and income loss in patients with early and advanced Parkinson’s disease
by Scott Johnson & Matthew Davis & Anna Kaltenboeck & Howard Birnbaum & ElizaBeth Grubb & Marcy Tarrants & Andrew Siderowf - 377-387 Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population
by Noam Kirson & Howard Birnbaum & Jasmina Ivanova & Tracy Waldman & Vijay Joish & Todd Williamson - 389-402 An application of a proposed framework for formulary listing in low-income countries
by Vakaramoko Diaby & Jean Lachaine - 403-417 A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland
by Kurt Lippuner & Richard Pollock & Jayne Smith-Palmer & Thomas Meury & William Valentine
September 2011, Volume 9, Issue 5
- 281-292 Nutrition therapy cost analysis in the US
by Robin Turpin & Todd Canada & Frank Liu & Catherine Mercaldi & Alessandro Pontes-Arruda & Paul Wischmeyer - 305-315 Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE Clinical trial
by Michael Kattan & Stephanie Earnshaw & Cheryl McDade & Libby Black & Gerald Andriole - 331-347 Early assessment of medical technologies to inform product development and market access
by Maarten Ijzerman & Lotte Steuten - 348-348 Erratum to: Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis
by D. Mueller & A. Gandjour
July 2011, Volume 9, Issue 4
- 209-215 Design of patient access schemes in the UK
by Szymon Jarosławski & Mondher Toumi - 217-223 Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices
by Brian Gazzard & Andrew Hill & Anne Anceau - 225-241 Ordering errors, objections and invariance in utility survey responses
by Eve Wittenberg & Lisa Prosser - 243-258 The use of decision-analytic models in Parkinson’s disease
by James Shearer & Colin Green & Carl Counsell & John Zajicek - 259-273 Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis
by Dirk Mueller & Afschin Gandjour - 275-279 Drugs for rare diseases: Influence of orphan designation status on price
by Eline Picavet & Marc Dooms & David Cassiman & Steven Simoens
May 2011, Volume 9, Issue 3
- 137-138 The economics of the NHS cancer drugs fund
by Alan Maynard & Karen Bloor - 139-148 The impact of inclusion criteria in health economic assessments
by Anke Richter & Patricia Thieda & Kylie Thaler & Gerald Gartlehner - 149-156 Valuing health at different ages
by Daniel Eisenberg & Gary Freed & Matthew Davis & Dianne Singer & Lisa Prosser - 157-169 Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation
by Katherine Stevens - 171-181 Patent extension policy for paediatric indications
by Richard Nelson & Carrie McAdam-Marx & Megan Evans & Robert Ward & Benjamin Campbell & Diana Brixner & Joanne Lafleur - 183-196 Cost effectiveness of tobacco control policies in Vietnam
by Hideki Higashi & Khoa Truong & Jan Barendregt & Phuong Nguyen & Mai Vuong & Thuy Nguyen & Phuong Hoang & Angela Wallace & Tien Tran & Cuong Le & Christopher Doran - 197-207 Hospital costs, length of stay and mortality associated with childhood, adolescent and young Adult meningococcal disease in the US
by Keith Davis & Timothy Bell & Jacqueline Miller & Derek Misurski & Bela Bapat
March 2011, Volume 9, Issue 2
- 65-71 Germany’s decision rule for setting ceiling prices of drugs
by Afschin Gandjour - 73-79 Public and decision maker stated preferences for pharmaceutical subsidy decisions
by Jennifer Whitty & Paul Scuffham & Sharyn Rundle-Thielee - 81-87 Citizens’ preferences for brand name drugs for treating acute and chronic conditions
by Arina Denoth & Christophe Pinget & Jean-Blaise Wasserfallen - 89-99 Influenza vaccination in healthy working adults in Russia
by O. At’kov & A. Azarov & D. Zhukov & N. Nicoloyannis & Laure Durand - 101-110 Influence of patient co-payments on atypical antipsychotic choice in Poland
by Magda Wladysiuk & Aleksander Araszkiewicz & Brian Godman & Katarzyna Szabert & Corrado Barbui & Alan Haycox - 111-123 Current and future economic burden of osteoporosis in New Zealand
by Paul Brown & Rob McNeill & William Leung & Eman Radwan & Jane Willingale - 125-136 Impact of fibromyalgia severity on health economic costs
by Andreas Winkelmann & Serge Perrot & Caroline Schaefer & Kellie Ryan & Arthi Chandran & Alesia Sadosky & Gergana Zlateva
January 2011, Volume 9, Issue 1
- 1-13 The Chinese healthcare system
by Jens Hougaard & Lars Østerdal & Yi Yu - 15-27 Valuing child health utility 9D health states with a young adolescent sample
by Julie Ratcliffe & Leah Couzner & Terry Flynn & Michael Sawyer & Katherine Stevens & John Brazier & Leonie Burgess - 29-37 Costs to hospitals of acquiring and processing blood in the US
by Richard Toner & Laura Pizzi & Brian Leas & Samir Ballas & Alyson Quigley & Neil Goldfarb - 39-49 Determinants of out-of-pocket health expenditure in China
by Xuedan You & Yasuki Kobayashi - 51-64 The impact of CT colonography for colorectal cancer screening on the UK NHS
by Alison Sweet & David Lee & Kerry Gairy & Denver Phiri & Timothy Reason & Kevin Lock
November 2010, Volume 8, Issue 6
- 361-371 The missing technology
by Bianca Frogner - 393-405 Catastrophic healthcare payments and impoverishment in the occupied Palestinian territory
by Awad Mataria & Firas Raad & Mohammad Abu-Zaineh & Cam Donaldson
September 2010, Volume 8, Issue 5
- 281-300 Burden and cost of hospital admissions for vaccine-preventable paediatric pneumococcal disease and non-typable Haemophilus influenzae otitis media in New Zealand
by Richard Milne & Stephen Hoorn - 301-315 Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007
by Javier Orofino & Javier Soto & Miguel Casado & Itziar Oyagüez - 317-325 Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany
by Linus Jönsson & Åsa Eliasson & John Kindblom & Olle Almgren & Nils Edvardsson - 327-341 Cost effectiveness of long-acting risperidone in Sweden
by Marja Hensen & Bart Heeg & Mickael Löthgren & Ben Hout - 343-350 Issues surrounding orphan disease and orphan drug policies in Europe
by Alain Denis & Lut Mergaert & Christel Fostier & Irina Cleemput & Steven Simoens - 351-354 Economic efficiency of alcohol policy
by Christopher Doran & Thameemul Jainullabudeen
July 2010, Volume 8, Issue 4
- 217-223 Oncologist preferences for health states associated with the treatment of advanced ovarian cancer
by Lisa Hess & Daniel Malone & Grant Skrepnek & Pamela Reed & Edward Armstrong & Stephen Coons - 225-237 The effect of protest zeros on estimates of willingness to pay in healthcare contingent valuation analysis
by William Fonta & H. Ichoku & Jane Kabubo-Mariara - 239-249 Audit of Diabetes-Dependent Quality of Life (ADDQoL) [Chinese version for Singapore] questionnaire
by Swee Soon & Su Goh & Yong Bee & Jiat Poon & Shu Li & Julian Thumboo & Hwee Wee - 251-265 Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden
by J. Logman & Bart Heeg & Johan Herlitz & Ben Hout - 267-280 Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada
by Sandra Tunis & Luc Sauriol & Michael Minshall
May 2010, Volume 8, Issue 3
- 141-154 Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60–69 years
by David Lee & Dominic Muston & Alison Sweet & Chris Cunningham & Andrew Slater & Kevin Lock - 155-165 Public option and private profits
by Fabio Milani - 167-177 Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a medicaid programme
by Ying Qiu & Alex Fu & Gordon Liu & Dale Christensen - 179-189 Productivity loss resulting from coronary heart disease in Australia
by Henry Zheng & Fred Ehrlich & Janaki Amin - 191-202 Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany
by Thilo Schaufler & Malte Wolff - 203-214 A systematic data review of the cost of rehydration therapy
by Jay Pershad - 215-216 Gary Buurman, 1944–2010
by Stuart Birks
March 2010, Volume 8, Issue 2
- 75-88 Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment?
by Paul Farnham - 89-97 Health system choice
by Paul Scuffham & Jennifer Whitty & Matthew Taylor & Ruth Saxby - 99-109 Willingness to pay for maternal health outcomes
by Laura Ternent & Paul McNamee & David Newlands & Danielle Belemsaga & Adjima Gbangou & Suzanne Cross - 111-118 Outpatient medication costs of patients with cystic fibrosis in Germany
by Daniela Eidt-Koch & Thomas Wagner & Thomas Mittendorf & J.-Matthias Schulenburg - 119-128 Organization and estimated patient-borne costs of oral anticoagulation therapy in Italy
by Lorenzo Pradelli & Sergio Iannazzo & Orietta Zaniolo & Paola Botrugno - 129-140 Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder
by Regina Rendas-Baum & Min Yang & Joseph Gricar & Gene Wallenstein
December 2009, Volume 7, Issue 4
- 209-217 Which barriers prevent the efficient use of resources in medical device sectors?
by Steven Simoens - 219-224 Assessing comparative effectiveness research in the US
by Joshua Cohen & John Bridges - 225-227 Cost effectiveness of antiretrovirals — long term or short term?
by Steffen Flessa - 229-243 The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda
by Elliot Marseille & James Kahn & Christian Pitter & Rebecca Bunnell & William Epalatai & Emmanuel Jawe & Willy Were & Jonathan Mermin - 245-254 A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine
by Derek Misurski & Maureen Lage & Rosalind Fabunmi & Kristina Boye - 255-264 Cost savings associated with filling a 3-month supply of prescription medicines
by Atonu Rabbani & G. Alexander - 265-277 Demand for outpatient healthcare
by Sisira Sarma